Pascal Soriot, AstraZeneca CEO (Zach Gibson/Bloomberg via Getty Images)

Covid-19 roundup: As As­traZeneca deals with vac­cine woes, US turns at­ten­tion to its an­ti­body treat­ment; Mod­er­na dos­es first kids in pe­di­atric vac­cine study 

As coun­tries around the world halt the dis­tri­b­u­tion of As­traZeneca’s Covid-19 vac­cine due to re­ports of blood clots, the US is more fo­cused on the phar­ma’s an­ti­body treat­ment.

The US has se­cured half a mil­lion more dos­es of As­traZeneca’s long-act­ing an­ti­body com­bo AZD7442, build­ing on an ini­tial 100,000-dose deal struck back in Oc­to­ber, the com­pa­ny said on Tues­day. As­traZeneca al­so has a sep­a­rate agree­ment to sup­ply the De­part­ment of De­fense with 100,000 dos­es, bring­ing the US’ to­tal sup­ply or­der to 700,000 dos­es in 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.